Tech Company Financing Transactions
Tactiva Therapeutics Funding Round
Tactiva Therapeutics, based in Buffalo, secured $35 million from Panacea Capital Advisors, EFung Capital and VI Partners.
Transaction Overview
Company Name
Announced On
12/4/2018
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds of the financing will be used to advance the clinical development of Tactiva Therapeutics' dual enhanced adoptive cell therapy (DEACT) platform for the treatment of Multiple Myeloma and several solid tumor type cancer indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
701 Ellicott St.
Buffalo, NY 14202
USA
Buffalo, NY 14202
USA
Phone
Website
Email Address
Overview
Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy. We are taking the fight to cancer by developing next generation adoptive cell therapy (ACT) strategies that deliver lethal hits to cancer cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Colpoys
Chief Medical Officer
Kunle Odunsi
Chief Scientific Officer
Richard Koya
Browse more venture capital transactions:
Prev: 12/3/2018: Wave Computing venture capital transaction
Next: 12/4/2018: Streem venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records on this site come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs